Iambic Therapeutics, Inc. (IAM) Posts Updated IAM1363 Phase 1/1b Data

What happened

Iambic Therapeutics reported updated Phase 1/1b results for IAM1363, a brain-penetrant HER2 TKI, showing durable anti-tumor activity, intracranial responses, and favorable tolerability at 960 mg once daily in heavily pretreated HER2-altered cancers. Parts 3 and 4 are open to enrollment.

Confirmed

Global impact / market context

Positive early data can raise the chance a small biotech drug advances to later trials, which is a key value step. Brain responses and activity after prior HER2 therapies could widen the patient group if confirmed in larger studies.

Analyst inference

The update builds on prior 2025 ESMO data, strengthening an early proof-of-concept story. Investors likely focus on whether quantified response rates and durability, or a Phase 2 move, come next, since those would test the early signals.

Analyst inference

What to watch

1. Parts 3 and 4 of the trial are open to enrollment, which means the company is still recruiting patients for expansion and combination groups that could produce near-term data. Confirmed
2. A larger confirmatory dataset with quantified response rates and durability, or a move into Phase 2, would be the next catalyst, which means a clearer test of the drug's benefit. Proposed
3. Because many patients had cancer spread to the brain, confirming intracranial responses in more people would matter most; if they hold up, the drug could serve a high-need group. Analyst inference

Evidence

• Original source link unavailable